These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. de Reijke TM; de Boer EC; Kurth KH; Schamhart DH J Urol; 1996 Feb; 155(2):477-82. PubMed ID: 8558640 [TBL] [Abstract][Full Text] [Related]
50. Is intravesical chemotherapy for superficial bladder cancer still justified? Okeke AA; Probert JL; Gillatt DA; Schwaibold H BJU Int; 2005 Oct; 96(6):763-7. PubMed ID: 16153195 [No Abstract] [Full Text] [Related]
51. [Treatment of superficial transitional cell bladder carcinoma. Long-term results of trial comparing transurethral resection alone and adjuvant chemotherapy with Doxorubicin]. Milonas D; Mickevicius J; Mickevicius R; Motiejūnas A; Sukys D; Gudinaviciene I Medicina (Kaunas); 2002; 38 Suppl 1():79-83. PubMed ID: 12556642 [TBL] [Abstract][Full Text] [Related]
52. Intracavitary Bacillus Calmette-Guerin in the Treatment of Superficial Bladder Tumors. Morales A; Eidinger D; Bruce AW J Urol; 2017 Feb; 197(2S):S142-S145. PubMed ID: 28012770 [TBL] [Abstract][Full Text] [Related]
53. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Gofrit ON; Shapiro A; Pode D; Sidi A; Nativ O; Leib Z; Witjes JA; van der Heijden AG; Naspro R; Colombo R Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439 [TBL] [Abstract][Full Text] [Related]
54. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG). Pansadoro V; Emiliozzi P; depaula F; Scarpone P; Pizzo M; Federico G; Martini M; Pansadoro A; Sternberg CN J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):223-7. PubMed ID: 16767936 [TBL] [Abstract][Full Text] [Related]
55. Miliary tuberculosis of the lung in a patient treated with bacillus Calmette-Guerin for superficial bladder cancer. Iantorno R; Nicolai M; Storto ML; Ciccotosto C; Cipollone G; Mastroprimiano G; Tenaglia RL J Urol; 1998 May; 159(5):1639-40. PubMed ID: 9554372 [No Abstract] [Full Text] [Related]
57. [Our experience in treating patients with surface cancer of the bladder]. Matveev BP; Figurin KM; Romanov VA; Cheban NL Urol Nefrol (Mosk); 1995; (5):35-8. PubMed ID: 8571484 [TBL] [Abstract][Full Text] [Related]
58. Analysis of the effect of intravesical treatment with interferon-alpha 2b on the clinical evolution and on the in vivo function of T lymphocytes and natural killer cells in patients with superficial bladder tumors. Carballido J; Moltó LM; Olivier C; Manzano L; Alvarez-Mon M Anticancer Drugs; 1992 May; 3 Suppl 1():9-12. PubMed ID: 1611118 [TBL] [Abstract][Full Text] [Related]
59. The development of liposomes containing interferon alpha for the intravesical therapy of human superficial bladder cancer. Frangos DN; Killion JJ; Fan D; Fishbeck R; von Eschenbach AC; Fidler IJ J Urol; 1990 Jun; 143(6):1252-6. PubMed ID: 2342197 [TBL] [Abstract][Full Text] [Related]
60. New strategies in the treatment of Ta-T1 transitional cell carcinoma (TCC) of the bladder. Brausi MA ScientificWorldJournal; 2006 Oct; 6():2632-7. PubMed ID: 17619741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]